Appears on
Articles2
Prime wins patent fight with Beam to continue work on AATD gene editing therapy
Prime Medicine has come out ahead in its patent dispute with fellow gene-editing biotech Beam Therapeutics, after a panel of adjudicators ruled that the company did not violate its agreement with Beam and can continue developing its lead asset for alpha-1 antitrypsin deficiency.
0
Fierce Biotech17h agoFDA halts release of new drug rejection letters while working to formalize policy
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen’s petition from an unnamed pharma company in April.
0
Fierce Biotech15h ago